Mark J. Rosenblum
Net Worth

Last updated:

What is Mark J. Rosenblum net worth?

The estimated net worth of Mr. Mark J. Rosenblum is at least $2,831,300 as of 31 May 2022. He owns shares worth $860,250 as insider and has received compensation worth at least $1,971,050 in Salarius Pharmaceuticals, Inc..

What is the salary of Mark J. Rosenblum?

Mr. Mark J. Rosenblum salary is $394,210 per year as Executive Vice President of Fin. & Chief Financial Officer in Salarius Pharmaceuticals, Inc..

How old is Mark J. Rosenblum?

Mr. Mark J. Rosenblum is 72 years old, born in 1953.

What stocks does Mark J. Rosenblum currently own?

As insider, Mr. Mark J. Rosenblum owns shares in one company:

Company Title Shares Price per share Total value
Salarius Pharmaceuticals, Inc. (SLRX) Executive Vice President of Fin. & Chief Financial Officer 148,319 $5.8 $860,250

What does Salarius Pharmaceuticals, Inc. do?

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

SLRX logo
SLRX
Salarius Pharmaceuticals, Inc.
$5.8

Mark J. Rosenblum insider trading

Salarius Pharmaceuticals, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 28,000 $0.18 $5,040
Purchase
Common Stock 76,246 $0.39 $29,812
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 2,000 N/A N/A
Purchase
Common Stock 5,000 N/A N/A

Salarius Pharmaceuticals key executives

Salarius Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:

  • Mr. David J. Arthur M.B.A. (62) Chief Executive Officer, Pres & Director
  • Mr. Mark J. Rosenblum (72) Executive Vice President of Fin. & Chief Financial Officer